Matches in DBpedia 2015-10 for { <http://dbpedia.org/resource/CERC-501> ?p ?o }
Showing triples 1 to 79 of
79
with 100 triples per page.
- CERC-501 abstract "CERC-501 (formerly known as LY-2456302) is a selective, short-acting antagonist of the κ-opioid receptor (Ki = 0.81 nM vs. 24.0 nM and 155 nM for the μ- and δ-opioid receptors, respectively). The molecule is being developed as a psychiatric drug by Cerecor Inc. of Baltimore.It was originally developed by Eli Lily as an augmentation to antidepressant therapy for treatment-resistant depression, under the name LY-2456302, and was under phase II clinical trials in the United States. In animal models of depression, CERC-501 has been found to have potent synergistic efficacy in combination with other antidepressants such as citalopram and imipramine.In February 2015, Cerecor Inc. announced that they have acquired the rights to develop and commercialize the molecule.".
- CERC-501 atcPrefix "None".
- CERC-501 casNumber "1174130-61-0".
- CERC-501 iupacName "4-(4-{[(2S)-2-(3,5-Dimethylphenyl)-1-pyrrolidinyl]methyl}phenoxy)-3-fluorobenzamide".
- CERC-501 thumbnail LY-2456302.svg?width=300.
- CERC-501 wikiPageID "43221610".
- CERC-501 wikiPageLength "5543".
- CERC-501 wikiPageOutDegree "24".
- CERC-501 wikiPageRevisionID "659856966".
- CERC-501 wikiPageWikiLink ALKS-5461.
- CERC-501 wikiPageWikiLink Antidepressant.
- CERC-501 wikiPageWikiLink Baltimore.
- CERC-501 wikiPageWikiLink Category:Antidepressants.
- CERC-501 wikiPageWikiLink Category:Benzamides.
- CERC-501 wikiPageWikiLink Category:Kappa_antagonists.
- CERC-501 wikiPageWikiLink Category:Opioid_antagonists.
- CERC-501 wikiPageWikiLink Citalopram.
- CERC-501 wikiPageWikiLink Clinical_trial.
- CERC-501 wikiPageWikiLink Delta-opioid_receptor.
- CERC-501 wikiPageWikiLink Depression_(mood).
- CERC-501 wikiPageWikiLink Eli_Lilly_and_Company.
- CERC-501 wikiPageWikiLink Eli_Lily.
- CERC-501 wikiPageWikiLink Imipramine.
- CERC-501 wikiPageWikiLink JDTic.
- CERC-501 wikiPageWikiLink Kappa-opioid_receptor.
- CERC-501 wikiPageWikiLink Mu-opioid_receptor.
- CERC-501 wikiPageWikiLink NSI-189.
- CERC-501 wikiPageWikiLink PF-4455242.
- CERC-501 wikiPageWikiLink Phases_of_clinical_research.
- CERC-501 wikiPageWikiLink Psychiatric_medication.
- CERC-501 wikiPageWikiLink Rapastinel.
- CERC-501 wikiPageWikiLink Receptor_antagonist.
- CERC-501 wikiPageWikiLink Treatment-resistant_depression.
- CERC-501 wikiPageWikiLink United_States.
- CERC-501 wikiPageWikiLink Δ-opioid_receptor.
- CERC-501 wikiPageWikiLink Κ-opioid_receptor.
- CERC-501 wikiPageWikiLink Μ-opioid_receptor.
- CERC-501 wikiPageWikiLinkText "CERC-501".
- CERC-501 atcPrefix "None".
- CERC-501 c "26".
- CERC-501 casNumber "1174130".
- CERC-501 chemspiderid "28424203".
- CERC-501 eliminationHalfLife "-144000.0".
- CERC-501 f "1".
- CERC-501 h "27".
- CERC-501 hasPhotoCollection CERC-501.
- CERC-501 inchi "1".
- CERC-501 inchikey "ZHPMYDSXGRRERG-DEOSSOPVBF".
- CERC-501 iupacName "4".
- CERC-501 molecularWeight "418.503".
- CERC-501 n "2".
- CERC-501 o "2".
- CERC-501 routesOfAdministration "Oral".
- CERC-501 smiles "CC1=CCC".
- CERC-501 stdinchi "1".
- CERC-501 stdinchikey "ZHPMYDSXGRRERG-DEOSSOPVSA-N".
- CERC-501 wikiPageUsesTemplate Template:Antidepressants.
- CERC-501 wikiPageUsesTemplate Template:Drugbox.
- CERC-501 wikiPageUsesTemplate Template:Nervous-system-drug-stub.
- CERC-501 wikiPageUsesTemplate Template:Opioidergics.
- CERC-501 wikiPageUsesTemplate Template:Reflist.
- CERC-501 subject Category:Antidepressants.
- CERC-501 subject Category:Benzamides.
- CERC-501 subject Category:Kappa_antagonists.
- CERC-501 subject Category:Opioid_antagonists.
- CERC-501 hypernym Antagonist.
- CERC-501 type ChemicalSubstance.
- CERC-501 type Drug.
- CERC-501 type ChemicalObject.
- CERC-501 type Thing.
- CERC-501 type Q8386.
- CERC-501 comment "CERC-501 (formerly known as LY-2456302) is a selective, short-acting antagonist of the κ-opioid receptor (Ki = 0.81 nM vs. 24.0 nM and 155 nM for the μ- and δ-opioid receptors, respectively). The molecule is being developed as a psychiatric drug by Cerecor Inc. of Baltimore.It was originally developed by Eli Lily as an augmentation to antidepressant therapy for treatment-resistant depression, under the name LY-2456302, and was under phase II clinical trials in the United States.".
- CERC-501 label "CERC-501".
- CERC-501 sameAs m.0114mr1q.
- CERC-501 sameAs Q18344482.
- CERC-501 sameAs Q18344482.
- CERC-501 wasDerivedFrom CERC-501?oldid=659856966.
- CERC-501 depiction LY-2456302.svg.
- CERC-501 isPrimaryTopicOf CERC-501.